Harry interviews Ramy Farid, president and CEO of Schrödinger Pharmaceuticals, about the company’s success using chemical simulation software to help drug makers zero in on promising drug candidates—and about its recent IPO, which brought in more than twice as much cash as the company expected.
The content above was previously recorded. The views herein were made at the time of this recording and are not updated to reflect changes in economic or financial circumstances. The opinions are those of the contributor and not Scientia Ventures, LLC, its affiliates, officers, or employees. Nothing herein constitutes a recommendation, solicitation, or offer to purchase securities or private funds, which can only be made through the relevant offering documents.
